AU Patent

AU2014268177B2 — Crystalline solvates and complexes of (1s) -1, 5-anhydro-1-c-(3-((phenyl)methyl)phenyl)-d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes

Assigned to AstraZeneca AB · Expires 2016-05-19 · 10y expired

What this patent protects

Abstract The present invention relates to crystal forms of the compound of the formula I including complexes tmeof wherein the complex is formed as a co-crystal forn with proline or phenylaianine. The invention also discloses processes of ornming the crystal fons of formMla I and…

USPTO Abstract

Abstract The present invention relates to crystal forms of the compound of the formula I including complexes tmeof wherein the complex is formed as a co-crystal forn with proline or phenylaianine. The invention also discloses processes of ornming the crystal fons of formMla I and methods of treating diseases such as diabetes, glucose intolerance, insulin resistance and other conditions using such structures. OEt HO"'O

Drugs covered by this patent

Patent Metadata

Patent number
AU2014268177B2
Jurisdiction
AU
Classification
—
Expires
2016-05-19
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.